Extract to table
Pull the structured facts out of a document: parties, dates, amounts, obligations.
Extract to table / site-agreement-graystone-001.docx
site-agreement-graystone-001.docx
Parties
Penterra Pharmaceuticals Corp
Clinical Contracts Penterra Pharmaceuticals Corp
Sponsor Insurance Penterra Pharmaceuticals Corp
M. Best Company
Dates
June 28, 2023
July 18, 2023
August 14, 2023
July 5, 2023
April 1, 2023
March 31, 2024
Amounts
$80,000,000
$52,000
$13,000
$75,000
$37,500
$40,000
$140,000
$4,200,000
$300,000
$1,500,000
Obligations
1 — Definitions All capitalized terms used but not otherwise defined in this Individual Site Agreement shall have the respective meanings ascribed to such terms in the MCTA
2 of the MCTA and that, upon execution and delivery of this Agreement by all Parties hereto, the Institution shall be bound by all terms and conditions of the MCTA applicable to a "Participating Site" or "Site" thereunder
Any such site-specific superseding provision shall be clearly identified as such in this Agreement and shall apply solely to Site 001 and shall not affect the rights or obligations of any other participating site under the MCTA
3 — Lead Site Responsibilities In addition to the general obligations applicable to all participating sites under the MCTA, the Institution, in its capacity as the lead enrollment site (Site 001) for the CLARION trial, shall have the following additional responsibilities: (a) Protocol Training
The Institution shall serve as the primary site for the conduct of monitor qualification visits ("MQVs") by the CRO (Meridian Contract Research Organization, Inc
The Principal Investigator, in her capacity as Global Principal Investigator for Protocol PPC-4871-III, shall coordinate with the Sponsor's Senior Vice President, Clinical Development (Dr